Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

To evaluate for an association between 25-hydroxyvitamin D levels (vitamin D) and outcome measures in patients with melanoma after evaluation is controlled for systemic inflammatory response (SIR) on the basis of simultaneous C-reactive protein (CRP) measurement.

Who Took Part

The study group was 1,042 patients.

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80.

Plasma samples from 1,042 prospectively observed patients with melanoma were assayed for vitamin D and CRP.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

The associations of demographics and CRP with vitamin D were determined, followed by a determination of the association between vitamin D and stage and outcome measures from the date of blood draw.

The vitamin D level was considered sufficient if it was 30 to 100 ng/mL.

Kaplan-Meier and Cox regression analyses were performed.

What Was Measured

Topics PubMed links to this paper include C-Reactive Protein, Disease-Free Survival, Melanoma, Proportional Hazards Models and Vitamin D.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 1,042 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.